Rheumatoid Arthritis Blood Test: What to Check

Rheumatoid arthritis (RA) affects over 400,000 people in the United Kingdom and is one of the most common autoimmune conditions. Unlike osteoarthritis, which results from wear and tear on the joints, rheumatoid arthritis is driven by an immune system that mistakenly attacks the synovial membrane — the lining of the joints. This causes chronic inflammation, pain, swelling, stiffness, and, if untreated, irreversible joint destruction.

Early diagnosis is critical. Research consistently shows that initiating disease-modifying treatment within the first three months of symptom onset — the so-called "window of opportunity" — significantly improves long-term outcomes, reduces joint damage, and increases the likelihood of achieving remission. Blood tests play a central role in both diagnosing RA and monitoring disease activity once treatment has started.

The Diagnostic Blood Tests

Rheumatoid Factor (RF)

Rheumatoid factor is an antibody (usually IgM) directed against the Fc portion of IgG. It has been used in the diagnosis of RA for decades. RF is positive in approximately 70% of people with RA, and higher titres are generally associated with more aggressive disease, increased joint damage, and extra-articular manifestations (such as rheumatoid nodules, vasculitis, and lung involvement).

However, RF has significant limitations. It is not specific to RA — it can be positive in other autoimmune conditions (Sjogren's syndrome, systemic lupus erythematosus), chronic infections (hepatitis C, tuberculosis), and even in 5–10% of healthy individuals, particularly the elderly. A positive RF without the right clinical picture does not diagnose RA, and a negative RF does not exclude it. Approximately 30% of RA patients are "seronegative" — they have RA but a negative RF.

Anti-CCP Antibodies (Anti-Cyclic Citrullinated Peptide)

Anti-CCP is the more modern and more specific test for rheumatoid arthritis. While its sensitivity is similar to RF (approximately 60–75%), its specificity is considerably higher — exceeding 95%. This means that a positive anti-CCP result is very strongly suggestive of RA and rarely occurs in other conditions.

What makes anti-CCP particularly valuable is that it can be positive years before symptoms appear. Studies of stored blood samples from military personnel who later developed RA found that anti-CCP antibodies were detectable up to 10 years before clinical disease onset. This has implications for people with a family history of RA or those with non-specific joint symptoms who want to understand their risk.

Anti-CCP positivity is also prognostic. Patients who are anti-CCP positive tend to have more erosive (joint-damaging) disease than those who are anti-CCP negative. This information helps rheumatologists make treatment decisions — anti-CCP positive patients may be started on more aggressive therapy earlier.

Interpreting the Combinations

The diagnostic significance varies depending on which antibodies are positive:

• RF positive + Anti-CCP positive: Strongly suggestive of RA with a higher risk of erosive disease. This combination has the highest positive predictive value.
• RF negative + Anti-CCP positive: Still highly suggestive of RA. Anti-CCP alone has excellent specificity.
• RF positive + Anti-CCP negative: Consider RA but also other causes of RF positivity. Clinical correlation is essential.
• RF negative + Anti-CCP negative: Does not exclude RA — approximately 20% of RA patients are double seronegative. Diagnosis in this group relies more heavily on clinical presentation and imaging.

Inflammatory Markers: Measuring Disease Activity

C-Reactive Protein (CRP)

CRP is an acute-phase protein produced by the liver in response to inflammation. It rises and falls rapidly (within hours), making it a useful real-time indicator of inflammatory activity. In RA, CRP levels correlate with disease activity — higher CRP generally means more active inflammation. The normal range is below 5 mg/L, though some laboratories report high-sensitivity CRP (hs-CRP) with a reference range below 3 mg/L.

CRP is used to calculate the DAS28-CRP (Disease Activity Score in 28 joints), which is the standard tool used by rheumatologists to assess disease activity and guide treatment decisions. A DAS28-CRP below 2.6 is considered remission. Monitoring CRP over time helps track whether treatment is controlling the inflammatory process.

ESR (Erythrocyte Sedimentation Rate)

ESR measures how quickly red blood cells settle to the bottom of a test tube over one hour. It is a less specific marker than CRP — it is influenced by age, sex, anaemia, and other factors — but it provides complementary information. ESR tends to change more slowly than CRP, reflecting longer-term inflammatory trends rather than acute fluctuations. The DAS28-ESR is an alternative disease activity calculation that some rheumatology units prefer.

Normal ESR is generally below 20 mm/hr for men and below 30 mm/hr for women, with some age-based variation. In active RA, ESR levels of 40–80+ mm/hr are common. A persistently elevated ESR despite treatment suggests inadequate disease control.

Full Blood Count: The Overlooked Essentials

A full blood count (FBC) provides important information in the context of RA that is often underappreciated.

Anaemia of Chronic Disease

Anaemia is the most common extra-articular manifestation of RA, affecting 30–60% of patients. The typical pattern is anaemia of chronic disease — characterised by a low haemoglobin with normal or elevated ferritin and low serum iron. This occurs because chronic inflammation disrupts iron metabolism through the hepcidin pathway, effectively sequestering iron in storage sites and making it unavailable for red blood cell production. Identifying this pattern is important because it is treated by controlling the underlying RA inflammation, not by iron supplementation.

Platelet Count

Thrombocytosis (elevated platelet count) is common in active RA and correlates with disease activity and inflammation. It is a reactive process — the platelets are being produced in response to inflammatory cytokines. Conversely, a low platelet count in an RA patient should prompt consideration of medication side effects (particularly methotrexate or other disease-modifying drugs) or an alternative diagnosis such as Felty syndrome.

White Blood Cell Count

The white cell count provides safety monitoring information, particularly for patients on immunosuppressive medications. Leucopenia (low white cells) can occur with methotrexate, leflunomide, and biological therapies. A neutrophil count below 1.0 × 10⁹/L generally warrants holding treatment and discussing with the rheumatology team.

Liver and Kidney Function: Baseline and Monitoring

Liver and kidney function tests are essential in RA for two reasons. Firstly, they provide a baseline before starting disease-modifying antirheumatic drugs (DMARDs). Methotrexate, the anchor drug in RA treatment, is hepatotoxic in a dose-dependent manner and is contraindicated in significant liver disease. Leflunomide is also hepatotoxic. Establishing baseline ALT, AST, and albumin levels before starting treatment allows for meaningful comparison during monitoring.

Secondly, once on treatment, regular liver and kidney function monitoring is mandatory. NICE and the British Society for Rheumatology recommend blood monitoring every 2 weeks for the first 6 weeks of methotrexate, then monthly for 3 months, and then at least every 3 months thereafter. An ALT rise to more than twice the upper limit of normal usually triggers a dose reduction or temporary cessation.

Kidney function (creatinine, eGFR) is particularly important for patients taking NSAIDs (non-steroidal anti-inflammatory drugs), which are commonly used for symptom relief in RA and carry a risk of renal impairment, especially with long-term use.

Additional Markers Worth Considering

Vitamin D

Vitamin D deficiency is more prevalent in people with autoimmune conditions, including RA. Low vitamin D levels have been associated with higher disease activity and poorer treatment outcomes in RA. Given the already high prevalence of vitamin D deficiency in the UK population, testing and optimising levels is a sensible adjunct to standard RA management.

Uric Acid

While not directly related to RA, uric acid measurement can help differentiate RA from gout, which can present with similar joint inflammation. In clinical practice, distinguishing early RA from polyarticular gout or pseudogout can be challenging, and blood markers contribute to the differential diagnosis.

Testing Options at Lola Health

Our Peak Insights 70 blood test (£185) includes CRP, a full blood count, liver function, kidney function, iron studies, vitamin D, and B12 — providing the comprehensive baseline panel needed for assessing inflammatory and metabolic health in the context of suspected or diagnosed RA. Rheumatoid Factor, Anti-CCP antibodies, and ESR are available as add-on biomarkers for specific RA investigation.

When to Get Tested

If you are experiencing symmetrical joint pain and stiffness (particularly in the small joints of the hands and feet), morning stiffness lasting more than 30 minutes, joint swelling, fatigue, or if you have a family history of RA, blood testing is a practical first step. Early RA is a medical urgency — not an emergency, but a situation where weeks and months matter. The 2010 ACR/EULAR classification criteria for RA incorporate both RF and anti-CCP alongside clinical findings, and a blood test can provide objective data to support or expedite a rheumatology referral.

For those already diagnosed with RA and on treatment, regular blood monitoring is not optional — it is a core part of safe disease management. Tracking CRP, FBC, and liver and kidney function at the intervals recommended by your rheumatology team ensures that treatment is both effective and safe.

Key Takeaways

• Over 400,000 people in the UK have rheumatoid arthritis. Early treatment within 3 months of symptom onset significantly improves outcomes.
• Rheumatoid Factor is positive in approximately 70% of RA but is not specific — it occurs in other conditions and in healthy people.
• Anti-CCP antibodies are the most specific blood test for RA (95%+ specificity) and can be positive years before symptoms develop.
• CRP and ESR measure inflammation and disease activity — they guide treatment decisions and monitor response.
• Anaemia of chronic disease affects 30–60% of RA patients and is driven by inflammation, not iron deficiency.
• Liver and kidney function testing is essential both as a baseline and for ongoing safety monitoring of RA medications.

Blood tests cannot diagnose rheumatoid arthritis in isolation, but they provide critical pieces of the diagnostic puzzle and are indispensable for monitoring disease activity and treatment safety. Whether you are investigating new symptoms or managing an existing diagnosis, comprehensive blood testing is one of the most valuable tools available.